Company Description
TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms.
The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer.
It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor.
The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December, 2023.
TuHURA Biosciences, Inc. was incorporated in 1993 and is based in Tampa, Florida.TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. .
| Country | United States |
| Founded | 2009 |
| CEO | James Bianco |
Contact Details
Address: 10500 University Center Drive, Suite 110 Tampa, Florida 33612 United States | |
| Phone | 813 875 6600 |
| Website | tuhurabio.com |
Stock Details
| Ticker Symbol | HURA |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001498382 |
| ISIN Number | US8989201038 |
| Employer ID | 99-0360497 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Bianco | Chief Executive Officer |
| Dan Dearborn | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 25, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 8-K | Current Report |